MultiCorp International Inc (MCIC)

[HMB2010]

I read through the link re: Stanford technology. I am not threatened by their device due to the best application, in theory, is for1. cancer therapy monitoring for individualized (personalized) medicine. That reads to me as basically seeing how/if responding to treatments and tweeking/changing as needed. 2. for use to dx acute coronary syndrome incidents in ER setting. Both using blood serum samples.

They are both utilizing similair theories to mark proteins in attempt to identify and dx illness, but in different areas. Inflammation at cellular level is different than the "cancer markers" Stanford is trying to pin down.

Plenty of uses for both, Bioharp, is ahead on development and has far more applications, IMO.
GLTA, go XMDC